Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for Amicus Therapeutics (FOLD) over the last 16 years, with Dec 2024 value amounting to -$56.1 million.

  • Amicus Therapeutics' Income towards Parent Company rose 357.19% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.1 million, marking a year-over-year increase of 86.57%. This contributed to the annual value of -$56.1 million for FY2024, which is 62.99% up from last year.
  • Per Amicus Therapeutics' latest filing, its Income towards Parent Company stood at -$56.1 million for FY2024, which was up 62.99% from -$151.6 million recorded in FY2023.
  • Amicus Therapeutics' 5-year Income towards Parent Company high stood at -$56.1 million for FY2024, and its period low was -$276.9 million during FY2020.
  • Its 3-year average for Income towards Parent Company is -$148.1 million, with a median of -$151.6 million in 2023.
  • Data for Amicus Therapeutics' Income towards Parent Company shows a peak YoY skyrocketed of 62.99% (in 2024) over the last 5 years.
  • Over the past 5 years, Amicus Therapeutics' Income towards Parent Company (Yearly) stood at -$276.9 million in 2020, then increased by 9.53% to -$250.5 million in 2021, then rose by 5.55% to -$236.6 million in 2022, then skyrocketed by 35.92% to -$151.6 million in 2023, then surged by 62.99% to -$56.1 million in 2024.